Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The current head, John Crowley, a biotech executive and rare disease advocate, took over in March. GSK has spent slightly ...

the drugmaker’s senior vice president of oncology global product strategy. Enter: “Your Cancer Is Our Challenge,” a new ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

"Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product ... GSK opened 1.9-percent lower in London following the results update. Over-the ...

Phenylephrine is widely used in a variety of over-the-counter flu and cold medicines, including popular products such as Benadryl ... the ingredient Companies such as Procter & Gamble and GSK were ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

Since taking the helm of GSK in 2017, Walmsley has returned the company to growth with a focus on cancer and infectious diseases to counter a combination ... a new shadow over the shares.